$AVR

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day results for its DurAVR THV in 22 patients, showing favorable hemodynamics, no moderate/severe leaks, and no valve-related deaths. The trial is ongoing, with the PARADIGM study comparing DurAVR to other TAVRs. According to the company, the results are promising for long-term outcomes.

Anteris Technologies (ASX: AVR, NASDAQ: AVR) is developing the DurAVR transcatheter heart valve, designed to mimic a healthy aortic valve. The PARADIGM trial, with 1,000 patients, aims to assess its safety and effectiveness against existing TAVR devices. Anteris has secured regulatory clearance in France and Germany for the trial, expanding its European presence. The study's results will determine DurAVR's potential as a treatment for aortic stenosis.

Anteris Technologies (NASDAQ: AVR, ASX: AVR) received regulatory clearance from Germany's BfArM to expand its PARADIGM Trial for the DurAVR® Transcatheter Heart Valve. This allows patient recruitment in Germany, Europe's largest TAVR market, accelerating trial enrollment. The PARADIGM Trial aims to evaluate the safety and effectiveness of DurAVR® compared to existing TAVRs.

Cantor Fitzgerald maintained an Overweight rating and $15.00 price target for Anteris Technologies (AVR). The stock, trading at $6.45, has risen 41% over the past year. The firm reinforced its conviction in AVR's DurAVR device, citing clinical advantages and potential to disrupt the TAVR market. AVR has a market cap of $628.83 million and reported $2.24 million in revenue over the last twelve months.

Anteris Technologies Global Corp.'s average price target was reduced by analysts from $13.04 to $12.84, with a range of $9.19 to $16. This implies a 93% upside from the Oct. 12 closing price. The consensus rating remains 'Buy' among 6 analysts.

L1 Capital Pty Ltd purchased 272,695 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at $7.18 ($1.96M total) on 2026-10-06.

On October 6, 2026, 91 insider transactions were reported. Berkshire Hathaway bought 842,753 LENNAR CORP shares for $67.45M. BORR DRILLING LTD's Tor Olav Troim bought 1.5M shares. ANTERIS TECHNOLOGIES GLOBAL CORP's L1 Capital bought 648,455 shares. ACCELEVATION HOLDINGS CORP's CEO bought 200,000 shares. PROTHENA CORP's William P Scully bought 100,000 shares.

L1 Capital Pty Ltd purchased 884,809 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $7.58 ($7.51–$7.78, $6.71M total) across 2 trades over 2026-10-02 to 2026-10-05.

L1 Capital Pty Ltd purchased 397,226 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $7.62 ($7.60–$7.72, $3.03M total) across 2 trades over 2026-09-30 to 2026-10-01.